Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,268 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathway Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

ADRB3 Signaling Pathway in Human Adipose Tissue

NCT05634174
View directory record Official record
Conditions
Obesity, Prediabetes
Interventions
Mirabegron
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

NCT04158336
View directory record Official record
Conditions
Solid Tumor
Interventions
Azenosertib
Drug
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Newport Beach, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Withdrawn Early Phase 1 Interventional

Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate

NCT04403568
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ursolic Acid, Curcumin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AQX-1125 in Unstable COPD

NCT01954628
View directory record Official record
Conditions
COPD
Interventions
AQX-1125, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

NCT03691207
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
AL101
Drug
Lead sponsor
Ayala Pharmaceuticals, Inc,
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting No phase listed Observational

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

NCT04489719
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
Procedure · Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Baltimore, Maryland • Bozeman, Montana • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Terminated Phase 1 Interventional

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT05037500
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Decitabine and Cedazuridine, Enzalutamide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Not applicable Interventional

Trial to Test the Effectiveness of Vibrotactile Stimulation for Lower Limb Spasticity

NCT07447934
View directory record Official record
Conditions
Lower Limb Spasticity
Interventions
Vibrotactile Stimulation (Static Use), Vibrotactile Stimulation (Dynamic Use), Vibrotactile Stimulation (Neurophysiological Mechanism)
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Not applicable Interventional

Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis

NCT07293871
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Active treatment, Sham (No Treatment)
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Colleyville, Texas • Dallas, Texas • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Cesarean Section Via Enhanced Recovery

NCT03552822
View directory record Official record
Conditions
Cesarean Section
Interventions
ERAS Protocol Implementation
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

NCT02141282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional

Physiological Changes Induced Through MEP Conditioning in People With SCI

NCT04286191
View directory record Official record
Conditions
Spinal Cord Injuries, Neurological Injury, Paralysis, Spasticity, Muscle
Interventions
Operant Conditioning, Control Group
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

NCT03263650
View directory record Official record
Conditions
Prostate Cancer Aggressiveness, Prostate Carcinoma
Interventions
Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Results available

Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer

NCT02517268
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Pancreaticoduodenectomy
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Vascular and Neurocognitive Health

NCT06497413
View directory record Official record
Conditions
Cognitive Decline, Cognitive Dysfunction, Alzheimer Disease, Vascular Disease, Peripheral
Interventions
Transcranial Photobiomodulation, Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered
Device
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional

FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer

NCT00323011
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 28, 2026, 5:06 PM EDT
Completed No phase listed Observational

Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting

NCT05091931
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Not listed
Lead sponsor
Pathnostics
Industry
Eligibility
18 Years and older
Enrollment
3,308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Not applicable Interventional

Pathways to Perinatal Mental Health Equity

NCT06790641
View directory record Official record
Conditions
Perinatal Anxiety, Perinatal Depression, Social Determinants of Health (SDOH), Peer Support, Obstetric Care, Substance Use Disorder (SUD), Perinatal Depression, Substance Use
Interventions
Program in Support of Moms (PRISM), PSI Peer Support
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 70 Years
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Shrewsbury, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Study of SRF617 in Patients With Advanced Solid Tumors

NCT04336098
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Phase 2 Interventional

Ulixertinib in People With Histiocytic Neoplasms

NCT06411821
View directory record Official record
Conditions
Histiocytic Neoplasms
Interventions
Ulixertinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Rochester, Minnesota • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Terminated Phase 1 Interventional

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

NCT01088763
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study, dexamethasone
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 28, 2026, 5:06 PM EDT
Completed No phase listed Observational

Genomic Determinants and Shared Genetic Pathways of Periodontal Disease

NCT03437798
View directory record Official record
Conditions
Periodontal Diseases, Diabetes, Osteoporosis, Cardiovascular Risk Factor
Interventions
Disease status
Other
Lead sponsor
Tufts University
Other
Eligibility
45 Years to 100 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 28, 2026, 5:06 PM EDT
Enrolling by invitation No phase listed Observational

Contribution of Bone to Urine Citrate

NCT06811363
View directory record Official record
Conditions
Osteoporosis
Interventions
Metabolic / prescribed diet, KCit Load (40 meq), Anti-resorptive agents, Anabolic Agents
Other · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 28, 2026, 5:06 PM EDT